Several other equities analysts have also issued reports on OPK. Deutsche Bank AG reduced their target price on Opko Health from $11.00 to $10.00 and set a hold rating for the company in a report on Thursday, June 16th. Jefferies Group reaffirmed a hold rating and issued a $10.00 target price (down from $11.00) on shares of Opko Health in a report on Friday, June 17th. Standpoint Research upped their target price on Opko Health from $16.00 to $18.00 and gave the company a buy rating in a report on Tuesday, June 21st. Zacks Investment Research downgraded Opko Health from a hold rating to a sell rating in a research note on Friday, July 1st. Finally, JPMorgan Chase & Co. set a $14.00 price objective on Opko Health and gave the company a buy rating in a research note on Tuesday, August 9th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Opko Health has an average rating of Buy and a consensus price target of $13.20.
Opko Health (NYSE:OPK) opened at 9.56 on Monday. The company has a market cap of $5.26 billion and a price-to-earnings ratio of 40.00. Opko Health has a 1-year low of $7.12 and a 1-year high of $11.85. The firm’s 50-day moving average price is $10.06 and its 200-day moving average price is $10.08.
Opko Health (NYSE:OPK) last released its earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.05. The business earned $357.10 million during the quarter, compared to the consensus estimate of $324.11 million. The business’s revenue was up 742.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.09) earnings per share. Equities research analysts forecast that Opko Health will post ($0.05) EPS for the current fiscal year.
In related news, CEO Phillip Md Et Al Frost bought 7,200 shares of the company’s stock in a transaction on Tuesday, October 11th. The shares were purchased at an average price of $9.78 per share, for a total transaction of $70,416.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares in the company, valued at approximately $30,014,340.78. The transaction was disclosed in a filing with the SEC, which is available at this link.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in OPK. ProShare Advisors LLC purchased a new position in Opko Health during the second quarter valued at $100,000. Financial Architects Inc boosted its position in Opko Health by 21.5% in the second quarter. Financial Architects Inc now owns 10,950 shares of the company’s stock valued at $102,000 after buying an additional 1,940 shares during the last quarter. First Citizens Bank & Trust Co. purchased a new position in Opko Health during the second quarter valued at $103,000. Williams Jones & Associates LLC boosted its position in Opko Health by 352.0% in the second quarter. Williams Jones & Associates LLC now owns 11,300 shares of the company’s stock valued at $106,000 after buying an additional 8,800 shares during the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in Opko Health by 23.0% in the second quarter. Janney Montgomery Scott LLC now owns 13,284 shares of the company’s stock valued at $134,000 after buying an additional 2,485 shares during the last quarter.
Opko Health Company Profile
OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.
Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.